iBio Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Basis of Presentation (Narrative) (Details)

Basis of Presentation (Narrative) (Details)											1 Months Ended	3 Months Ended		9 Months Ended
Basis of Presentation (Narrative) (Details)	Apr. 01, 2024 USD ($) $ / shares shares	Mar. 26, 2024 USD ($) $ / shares shares	Feb. 25, 2024 USD ($)	Dec. 07, 2023 USD ($) $ / shares shares	Dec. 05, 2023 USD ($) shares	Nov. 27, 2023	Oct. 01, 2023 USD ($) shares	Nov. 03, 2022 position	Oct. 07, 2022	Sep. 22, 2022	Apr. 30, 2024 USD ($) shares	Mar. 31, 2024 USD ($) $ / shares shares	Dec. 31, 2023 shares	Mar. 31, 2024 USD ($) $ / shares shares	Mar. 31, 2023 USD ($)	May 13, 2024 USD ($)	Sep. 30, 2023 $ / shares	Jun. 30, 2023 USD ($) $ / shares	Nov. 30, 2022 ft²	Jun. 30, 2022 USD ($)	Nov. 01, 2021 USD ($)
Basis of Presentation [Line Items]
Percentage of workforce reduction								60.00%
Number of positions reduced \| position								69
Operations ceased, area of land \| ft²																			130,000
Common stock, par value (in dollars per share) \| $ / shares												$ 0.001		$ 0.001				$ 0.001
Warrants, exercise price per share \| $ / shares		$ 0.0001
Gross proceeds				$ 4,500,000
Sale proceeds for intangible assets			$ 1,000,000									$ 1,000,000.0		$ 1,000,000	$ 0
Potential contingent payment			2,500,000
Second potential contingent payment			$ 50,000,000
Number of warrants exercised \| shares												4,276,000
Proceeds from exercise of warrants												$ 4,276,000
Cash, cash equivalents and restricted cash												6,431,000		6,431,000	$ 9,782,000			$ 7,579,000		$ 28,672,000
Restricted Cash												1,100,000		1,100,000
Restricted cash, current												$ 914,000		$ 914,000				3,025,000
Reverse stock split, shares received per share tendered						0.05			0.04	0.04
Subsequent Event
Basis of Presentation [Line Items]
Proceeds from exercise of warrants											$ 192,000
Proceeds from sale of shares, net of issuance cost	$ 14,100,000
Cash, cash equivalents and restricted cash																$ 17,900,000
Restricted cash, current																$ 1,100,000
Pre Funded Warrants
Basis of Presentation [Line Items]
Number of warrants exercised \| shares												414,000	1,236,000
Series C Warrants
Basis of Presentation [Line Items]
Number of warrants exercised \| shares												1,131,500
Series C Warrants \| Subsequent Event
Basis of Presentation [Line Items]
Number of warrants exercised \| shares											48,000
Series D Warrants
Basis of Presentation [Line Items]
Number of warrants exercised \| shares												1,006,500
Series D Warrants \| Subsequent Event
Basis of Presentation [Line Items]
Number of warrants exercised \| shares											48,000
At-The-Market Offerings
Basis of Presentation [Line Items]
Shares sold \| shares														170,989
Proceeds from offering														$ 1,700,000
Common stock, par value (in dollars per share) \| $ / shares																	$ 0.001
Lincoln Park Purchase Agreement
Basis of Presentation [Line Items]
Shares sold \| shares							21,457							181,141
Proceeds from offering							$ 100,000							$ 1,200,000
Offering 2023
Basis of Presentation [Line Items]
Shares sold \| shares				600,000	600,000
Proceeds from sale of shares, net of issuance cost					$ 4,000,000
Offering 2023 \| Pre Funded Warrants
Basis of Presentation [Line Items]
Number of warrants issued \| shares				1,650,000
Warrants to purchase shares of Common Stock \| shares				1,650,000	1,650,000
Warrants, exercise price per share \| $ / shares				$ 0.0001
Offering 2023 \| Series C Warrants
Basis of Presentation [Line Items]
Number of warrants issued \| shares				2,250,000
Warrants to purchase shares of Common Stock \| shares				2,250,000	2,250,000
Warrants, exercise price per share \| $ / shares				$ 2.00
Term of the warrants				2 years
Offering 2023 \| Series D Warrants
Basis of Presentation [Line Items]
Number of warrants issued \| shares				2,250,000
Warrants to purchase shares of Common Stock \| shares				2,250,000	2,250,000
Warrants, exercise price per share \| $ / shares				$ 2.00
Term of the warrants				5 years
Private placement
Basis of Presentation [Line Items]
Shares sold \| shares		2,701,315
Common stock, par value (in dollars per share) \| $ / shares		$ 0.001
Gross proceeds		$ 15,100,000
Share price \| $ / shares		$ 2.85
Placement agent fees paid (as percentage)		6.00%
Reduced placement agent fees paid (as percentage)		4.00%
Payment made to placement agent for legal fees and other out of pocket expenses		$ 50,000
Private placement \| Subsequent Event
Basis of Presentation [Line Items]
Shares sold \| shares	2,701,315
Proceeds from sale of shares, net of issuance cost	$ 14,100,000
Private placement \| Pre Funded Warrants
Basis of Presentation [Line Items]
Warrants to purchase shares of Common Stock \| shares		2,585,963
Warrants, exercise price per share \| $ / shares		$ 0.0001
Share price \| $ / shares		$ 2.849
Private placement \| Pre Funded Warrants \| Subsequent Event
Basis of Presentation [Line Items]
Warrants to purchase shares of Common Stock \| shares	2,585,963
Warrants, exercise price per share \| $ / shares	$ 0.0001
Private placement \| Series E Warrants
Basis of Presentation [Line Items]
Warrants to purchase shares of Common Stock \| shares	5,287,278	5,287,278
Warrants, exercise price per share \| $ / shares		$ 2.64										$ 0		$ 0
Term of the warrants		5 years
Share price \| $ / shares		$ 2.849
Private placement \| Series E Warrants \| Subsequent Event
Basis of Presentation [Line Items]
Warrants, exercise price per share \| $ / shares	$ 2.64
Term of the warrants	5 years
Share price \| $ / shares	$ 2.849
Secured Term Loan
Basis of Presentation [Line Items]
Secured term loan																		13,057,000			$ 22,375,000
Debt balance outstanding												$ 12,655,000		$ 12,655,000				$ 12,937,000
Amended Credit Agreement [Member]
Basis of Presentation [Line Items]
Restricted Cash												$ 900,000		$ 900,000